Issue 24, 2023

A CaCO3-based synergistic immunotherapy strategy for treating primary and distal tumors

Abstract

Low response rate limits the widespread application of cancer immunotherapy. To improve the response rate of immunotherapy, a CaCO3-based composite nanomaterial was developed to induce immunogenic cell death for enhancing immunotherapy against 4T1 primary and distal tumors.

Graphical abstract: A CaCO3-based synergistic immunotherapy strategy for treating primary and distal tumors

Supplementary files

Article information

Article type
Communication
Submitted
30 Dec 2022
Accepted
24 Feb 2023
First published
25 Feb 2023

Chem. Commun., 2023,59, 3562-3565

A CaCO3-based synergistic immunotherapy strategy for treating primary and distal tumors

K. Tang, X. Zhang, J. Yin, W. Pan, Y. Li, N. Li and B. Tang, Chem. Commun., 2023, 59, 3562 DOI: 10.1039/D2CC07076F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements